Andrew Hirsch

Biography

Andrew Hirsch joined the Editas board of directors in May 2017 with more than 20 years of experience in a range of strategic and range of strategic and operating roles in business, including more than 15 years in the biotech industry. Since September 2016, he has served as Chief Financial Officer at Agios, a biopharmaceutical company in the fields of cancer metabolism and rare genetic diseases. Prior to joining Agios, Mr. Hirsch served as President and Chief Executive Officer of BIND Therapeutics and previously as Chief Financial Officer at Avila Therapeutics until its acquisition by Celgene. Prior to that, he held roles of increasing responsibility during his nearly 10-year tenure at Biogen, including Vice President of Corporate Strategy and M&A, as well as Program Executive for the Tecfidera development team. Mr. Hirsch holds an MBA from the Tuck School at Dartmouth College and a Bachelor of Arts in Economics from the University of Pennsylvania.

Research Interest

pharmaceuticals